SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a fresh 52-week high amid anticipation of its Q3 earnings report and continued optimism around BRIUMVIs growth. Traders debate whether the rally reflects earnings expectations and business momentum or buyout and short-covering speculation; a potential acquisition remains unconfirmed.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure amid approaching midterms, with traders focusing on reports that Trump canceled campaign rallies and on expectations of Democratic gains that could bring greater scrutiny of his administration. Bearish posts dominate, while some bulls argue the selloff could reverse after the election.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

A sharp pullback in ALAB has traders focused on whether it can hold key chart support ahead of earnings, with the report and guidance viewed as a potential catalyst. Bulls call the drop an opportunity amid continued AI data-center demand, while bears point to the stocks rich valuation and concerns about a broader AI-trade slowdown.

Polkadot (DOT) is a cryptocurrency . Polkadot has a current supply of 1,709,841,036.25825711. The last known price of Polkadot is 0.97593633 USD and is up 7.16 over the last 24 hours. It is currently trading on 1075 active market(s) with $102,857,730.92 traded over the last 24 hours. More information can be found at https://polkadot.com.

Polkadot

Polkadot is drawing attention after a prolonged decline pushed DOT below the psychologically important one-dollar level and toward new lows. Traders are split between calling it a demandless, failing project and treating the depressed price as an accumulation opportunity; some cite the proposed dotUSD stablecoin and Polkadot 2.0 developments as longer-term bullish narratives, while recent rebounds have prompted questions about what is driving them.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines results and weaker outlook have focused attention on soaring jet-fuel costs, which are squeezing margins despite strong revenue and travel demand. Traders are divided between concerns about losses and the airlines heavy debt burden, and hopes that lower fuel prices and premium demand could support a recovery.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors approaching FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, the revised upper-limb data, and recent commercial job postings. Some see FDA flexibility and INOs approval as encouraging signals, while others caution that hiring is not proof of approval and cite the prior AdCom concerns and efficacy debate.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo shares are under pressure after MaxLinear outlined plans to compete in the 1.6T active electrical cable market, which Credo currently dominates. Traders are debating whether the competitive threat is meaningful given Credos incumbent position, while broader weakness in AI and semiconductor stocks and concern about insider selling add to the unease.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Federal cannabis rescheduling is the dominant topic, with traders focused on procedural delays in the DEA process and uncertainty around when a Schedule III decision could arrive. Some see the delays and resulting weakness as an overreaction and a potential buying opportunity, while others are frustrated that the catalyst remains uncertain and has not supported the shares.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTXs sharp drop is drawing dip-buying and rebound speculation, while bearish traders warn that further weakness in Bitcoin or Strategy (MSTR) could deepen losses. The debate also centers on the funds 2x daily leverage and volatility decay, which can erode returns when held through choppy markets.

Sui (SUI) is a cryptocurrency launched in 2023. Sui has a current supply of 10,000,000,000 with 4,118,270,447.6403894 in circulation. The last known price of Sui is 0.90640557 USD and is up 4.19 over the last 24 hours. It is currently trading on 998 active market(s) with $545,881,218.06 traded over the last 24 hours. More information can be found at https://sui.io/.

SUI is drawing attention amid a volatile rebound, with traders debating whether the move signals renewed altcoin strength or a short-lived bounce. Bullish posts point to broader crypto momentum and adoption narratives such as Tethers tokenization platform, while skeptics cite token unlocks, supply concerns, and weak performance versus other cryptocurrencies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug

Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.read more...

Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?

Equity

Aclaris announced plans to sell about 7.8 million shares and pre-funded warrants at $3.50 each, a 7.65% discount to Monday’s closing price.


Are Medical Stocks Lagging  Aclaris Therapeutics (ACRS) This Year?

Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On...

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim

Guggenheim upgraded Aclaris Therapeutics to a "strong-buy" rating in a research report on Monday...

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The offering includes participation from TCGX, RA Capital Management, Invus and a large mutual fund.</li><li>In an atopic dermatitis trial, patients receiving the experimental ATI-052 showed a 58% improvement in skin disease severity after 57 days.</li><li>Aclaris plans to prioritize Phase 2b development in early 2027 for eosinophilic esophagitis.</li></ul>Shares of Aclaris Therapeutics (ACRS) fell about 7.7% in pre-market trading on Tuesday as investors weighed a discounted $50 million share offering despite the biotech firm reporting positive early-stage trial results for its experimental asthma and eczema treatment.Aclaris announced plans to sell about 7.8 million shares and pre-funded warrants covering an additional 6.5 million shares at $3.50 each. This represents a 7.65% discount to Monday’s closing price.The offering includes participation from TCGX, RA Capital Management, Invus and a large mutual fund, the company said.<h2 class="st-heading-2">What Did The Trial Show?</h2>Separately, Aclaris reported positive Phase 1b results for ATI-052, an experimental antibody designed to block proteins involved in allergic inflammation. In a 14-patient atopic dermatitis trial, patients receiving ATI-052 showed a 58% improvement in skin disease severity after 57 days, compared with 13% for placebo.Separately, a 16-patient asthma trial showed a 59% reduction in an airway inflammation marker within 15 days, compared with 15% for placebo.The treatment was generally well tolerated, with no severe Grade 3 or 4 treatment-emergent adverse events or trial discontinuations caused by adverse events.Aclaris plans to prioritize Phase 2b development in early 2027 for eosinophilic esophagitis, a condition that causes inflammation of the esophagus.Aclaris is also developing Bosakitug for eczema and Modzatinib for inflammatory diseases. The company had $170.6 million in cash, cash equivalents, and marketable securities as of June 30, which management previously expected would fund operations through 2028.<h2 class="st-heading-2">Retail Remains Bullish On ACRS</h2>Retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/ACRS">ACRS</a> on Stocktwits remained ‘bullish’ over the past 24 hours despite the pre-market slide.&nbsp;&nbsp;<img src="https://news.stocktwits-cdn.com/ACRS_1_b680756452.png" alt="ACRS (1).png">The stock has seen some buying interest so far in 2026, gaining more than 31%.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-finds-a-spot-on-bofa-top-stock-picks-list-as-falcon9-delivers-27-starlink-satellites-to-orbit/cZUeEV2RBC4">SPCX Finds A Spot On BofA’s Top Stock Picks List As Falcon 9 Delivers 27 Starlink Satellites To Orbit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

- The offering includes participation from TCGX, RA Capital Management, Invus and a large mutual fund.

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.97
Prev Close	$3.99
Open	$4.00
Dividend Yield	0.00%
50-Day Moving Average	$4.88
Beta	1.16
Avg. Volume	2.71M
PE Ratio	-6.79

52-Week High	$6.60
52-Week Low	$2.10
Market Capitalization	$584.38M
EPS (Annual)	-$0.5297
Price to Book	4.46
Revenue Per Employee	$107,205.48

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACRS Fundamentals